source
- AbbVie says Skyrizi maintains strong sales momentum as competition risesAbbVie highlighted that its immunology drug Skyrizi continues to generate robust sales despite increasing competition in the market. The company noted that demand for the therapy remains solid and…
- Sanofi books over €1 billion impairment after ending eczema drug and halting two immunology programsSanofi disclosed that it will record more than €1.03 billion in impairment charges for the second quarter. The bulk of the charge stems from the decision to terminate development of an eczema trea…